Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Poison Control Centers | 6 | 2023 | 14 | 2.810 |
Why?
|
| Cannabis | 3 | 2023 | 145 | 2.030 |
Why?
|
| Poisons | 2 | 2023 | 3 | 1.730 |
Why?
|
| Hallucinogens | 2 | 2023 | 62 | 1.610 |
Why?
|
| Poisoning | 5 | 2021 | 25 | 1.020 |
Why?
|
| Emergency Service, Hospital | 5 | 2022 | 486 | 0.900 |
Why?
|
| Pharmacogenetics | 1 | 2022 | 52 | 0.840 |
Why?
|
| Antidotes | 4 | 2021 | 29 | 0.810 |
Why?
|
| Methylene Blue | 1 | 2021 | 10 | 0.790 |
Why?
|
| Methemoglobinemia | 1 | 2021 | 6 | 0.790 |
Why?
|
| Manufactured Materials | 1 | 2021 | 2 | 0.780 |
Why?
|
| Mitragyna | 1 | 2021 | 9 | 0.770 |
Why?
|
| Emergencies | 5 | 2010 | 86 | 0.760 |
Why?
|
| Commerce | 1 | 2021 | 43 | 0.750 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2020 | 65 | 0.710 |
Why?
|
| Occupational Exposure | 1 | 2021 | 122 | 0.680 |
Why?
|
| Lead Poisoning | 1 | 2019 | 10 | 0.670 |
Why?
|
| Foreign Bodies | 1 | 2019 | 65 | 0.640 |
Why?
|
| Drug Utilization | 2 | 2015 | 77 | 0.530 |
Why?
|
| Child | 16 | 2022 | 6847 | 0.510 |
Why?
|
| Medical Order Entry Systems | 1 | 2015 | 12 | 0.500 |
Why?
|
| Adolescent | 11 | 2022 | 6356 | 0.480 |
Why?
|
| Vancomycin | 1 | 2015 | 81 | 0.470 |
Why?
|
| Humans | 32 | 2023 | 49974 | 0.470 |
Why?
|
| United States | 8 | 2022 | 4860 | 0.460 |
Why?
|
| Guideline Adherence | 1 | 2015 | 133 | 0.450 |
Why?
|
| Serotonin Syndrome | 1 | 2012 | 6 | 0.420 |
Why?
|
| Psychotropic Drugs | 2 | 2022 | 77 | 0.410 |
Why?
|
| Pediatrics | 2 | 2015 | 279 | 0.400 |
Why?
|
| Adult | 8 | 2022 | 13236 | 0.370 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 55 | 0.370 |
Why?
|
| Safety Management | 1 | 2010 | 38 | 0.370 |
Why?
|
| Adrenergic Agonists | 1 | 2010 | 8 | 0.360 |
Why?
|
| Reproduction | 2 | 2007 | 61 | 0.350 |
Why?
|
| Self Administration | 1 | 2010 | 102 | 0.340 |
Why?
|
| Epinephrine | 1 | 2010 | 96 | 0.340 |
Why?
|
| Male | 16 | 2021 | 25241 | 0.330 |
Why?
|
| Patient Care Team | 1 | 2010 | 254 | 0.330 |
Why?
|
| Antivenins | 2 | 2006 | 11 | 0.320 |
Why?
|
| Snake Bites | 2 | 2006 | 16 | 0.320 |
Why?
|
| Female | 15 | 2021 | 26472 | 0.320 |
Why?
|
| Child, Preschool | 10 | 2022 | 3871 | 0.310 |
Why?
|
| National Institute of Environmental Health Sciences (U.S.) | 1 | 2007 | 2 | 0.300 |
Why?
|
| Embryonic Development | 1 | 2007 | 17 | 0.300 |
Why?
|
| Toxicology | 1 | 2007 | 28 | 0.290 |
Why?
|
| Hydroxyurea | 1 | 2007 | 30 | 0.290 |
Why?
|
| Ibuprofen | 1 | 2007 | 21 | 0.290 |
Why?
|
| Acetaminophen | 2 | 2007 | 283 | 0.290 |
Why?
|
| Fever | 1 | 2007 | 114 | 0.270 |
Why?
|
| Retrospective Studies | 7 | 2022 | 6108 | 0.270 |
Why?
|
| Databases, Factual | 2 | 2022 | 658 | 0.270 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2007 | 117 | 0.260 |
Why?
|
| Young Adult | 4 | 2021 | 3958 | 0.260 |
Why?
|
| Snake Venoms | 1 | 2005 | 2 | 0.260 |
Why?
|
| Iron | 1 | 2006 | 122 | 0.250 |
Why?
|
| Chelation Therapy | 2 | 2019 | 4 | 0.240 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2004 | 9 | 0.240 |
Why?
|
| Parents | 1 | 2007 | 314 | 0.230 |
Why?
|
| Suicide, Attempted | 2 | 2021 | 76 | 0.230 |
Why?
|
| Infant | 7 | 2019 | 3567 | 0.230 |
Why?
|
| Psychomotor Agitation | 1 | 2004 | 51 | 0.230 |
Why?
|
| Violence | 1 | 2004 | 61 | 0.230 |
Why?
|
| Child Behavior Disorders | 1 | 2004 | 79 | 0.230 |
Why?
|
| Antipsychotic Agents | 1 | 2005 | 232 | 0.220 |
Why?
|
| Psychotic Disorders | 1 | 2004 | 133 | 0.210 |
Why?
|
| Suicidal Ideation | 1 | 2023 | 96 | 0.200 |
Why?
|
| Aged | 4 | 2021 | 9310 | 0.200 |
Why?
|
| Analgesics | 1 | 2022 | 100 | 0.200 |
Why?
|
| Seizures | 1 | 2003 | 195 | 0.190 |
Why?
|
| Diphenhydramine | 1 | 2021 | 19 | 0.190 |
Why?
|
| Middle Aged | 5 | 2021 | 12069 | 0.190 |
Why?
|
| Nonprescription Drugs | 1 | 2021 | 36 | 0.190 |
Why?
|
| Vertebral Artery Dissection | 1 | 2000 | 3 | 0.180 |
Why?
|
| Forecasting | 1 | 2021 | 150 | 0.180 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2002 | 173 | 0.180 |
Why?
|
| Cholinergic Antagonists | 2 | 2012 | 5 | 0.180 |
Why?
|
| Injections, Intramuscular | 3 | 2010 | 54 | 0.170 |
Why?
|
| Drug Overdose | 1 | 2021 | 159 | 0.160 |
Why?
|
| Eating | 1 | 2019 | 162 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 449 | 0.160 |
Why?
|
| Depression | 1 | 2002 | 568 | 0.140 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1557 | 0.130 |
Why?
|
| Drug Resistance, Microbial | 1 | 2015 | 46 | 0.120 |
Why?
|
| Nystagmus, Pathologic | 1 | 2014 | 4 | 0.120 |
Why?
|
| Miosis | 1 | 2014 | 6 | 0.120 |
Why?
|
| Mydriasis | 1 | 2014 | 4 | 0.120 |
Why?
|
| Detergents | 1 | 2014 | 16 | 0.120 |
Why?
|
| Quality Control | 1 | 2015 | 94 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 1037 | 0.120 |
Why?
|
| Esophagus | 1 | 2014 | 84 | 0.120 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 3129 | 0.110 |
Why?
|
| Endoscopy | 1 | 2014 | 124 | 0.110 |
Why?
|
| Conscious Sedation | 3 | 1999 | 24 | 0.110 |
Why?
|
| Methylphenidate | 2 | 2005 | 75 | 0.110 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 2012 | 4 | 0.110 |
Why?
|
| Malignant Hyperthermia | 1 | 2012 | 9 | 0.110 |
Why?
|
| Drug Therapy, Combination | 2 | 2012 | 377 | 0.100 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2012 | 11 | 0.100 |
Why?
|
| Shock | 1 | 2012 | 35 | 0.100 |
Why?
|
| Serotonin | 1 | 2012 | 152 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 2 | 2005 | 213 | 0.100 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2010 | 2 | 0.090 |
Why?
|
| Patient Identification Systems | 1 | 2010 | 5 | 0.090 |
Why?
|
| Electronic Prescribing | 1 | 2010 | 4 | 0.090 |
Why?
|
| Hospital Communication Systems | 1 | 2010 | 6 | 0.090 |
Why?
|
| Aviation | 1 | 2010 | 6 | 0.090 |
Why?
|
| Medical Errors | 1 | 2010 | 24 | 0.090 |
Why?
|
| Medication Errors | 1 | 2010 | 26 | 0.090 |
Why?
|
| Pregnancy | 3 | 2007 | 2607 | 0.090 |
Why?
|
| Social Responsibility | 1 | 2010 | 26 | 0.090 |
Why?
|
| Communication Barriers | 1 | 2010 | 33 | 0.090 |
Why?
|
| Health Resources | 1 | 2010 | 75 | 0.090 |
Why?
|
| Leadership | 1 | 2010 | 101 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2010 | 85 | 0.090 |
Why?
|
| Anaphylaxis | 1 | 2010 | 71 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 600 | 0.080 |
Why?
|
| Midazolam | 2 | 1999 | 38 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2010 | 209 | 0.080 |
Why?
|
| Administration, Oral | 3 | 2006 | 426 | 0.080 |
Why?
|
| Drug Administration Routes | 1 | 2007 | 10 | 0.080 |
Why?
|
| Chemical Warfare Agents | 1 | 2007 | 1 | 0.070 |
Why?
|
| Chemical Terrorism | 1 | 2007 | 1 | 0.070 |
Why?
|
| Methanol | 1 | 2006 | 10 | 0.070 |
Why?
|
| Ethylene Glycol | 1 | 2006 | 4 | 0.070 |
Why?
|
| Crotalid Venoms | 1 | 2006 | 9 | 0.070 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2006 | 16 | 0.070 |
Why?
|
| Immunoglobulin Fragments | 1 | 2006 | 15 | 0.070 |
Why?
|
| Syringes | 1 | 2006 | 13 | 0.070 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 26 | 0.070 |
Why?
|
| Health Care Surveys | 1 | 2007 | 173 | 0.070 |
Why?
|
| Deferoxamine | 1 | 2006 | 9 | 0.070 |
Why?
|
| Siderophores | 1 | 2006 | 6 | 0.070 |
Why?
|
| Acetylcysteine | 1 | 2006 | 100 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 206 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 376 | 0.070 |
Why?
|
| Growth and Development | 1 | 2005 | 15 | 0.070 |
Why?
|
| Vitamins | 1 | 2006 | 64 | 0.070 |
Why?
|
| Premedication | 2 | 1996 | 21 | 0.070 |
Why?
|
| Amphetamine | 1 | 2005 | 38 | 0.070 |
Why?
|
| Self Care | 1 | 2007 | 136 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2006 | 113 | 0.070 |
Why?
|
| Triage | 1 | 2006 | 62 | 0.070 |
Why?
|
| Nervous System | 1 | 2005 | 33 | 0.070 |
Why?
|
| Infertility | 1 | 2005 | 17 | 0.060 |
Why?
|
| Fentanyl | 2 | 1996 | 36 | 0.060 |
Why?
|
| Drug Interactions | 2 | 2003 | 206 | 0.060 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2005 | 94 | 0.060 |
Why?
|
| Developmental Disabilities | 1 | 2005 | 119 | 0.060 |
Why?
|
| Health Personnel | 1 | 2007 | 246 | 0.060 |
Why?
|
| Environmental Exposure | 1 | 2005 | 199 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 302 | 0.060 |
Why?
|
| Camphor | 1 | 2003 | 1 | 0.060 |
Why?
|
| Ginkgo biloba | 1 | 2003 | 8 | 0.060 |
Why?
|
| GABA Antagonists | 1 | 2003 | 11 | 0.060 |
Why?
|
| Phenytoin | 1 | 2003 | 17 | 0.060 |
Why?
|
| Methamphetamine | 1 | 2005 | 200 | 0.060 |
Why?
|
| Insecticides | 1 | 2003 | 15 | 0.060 |
Why?
|
| Isoniazid | 1 | 2003 | 37 | 0.060 |
Why?
|
| Seeds | 1 | 2003 | 25 | 0.060 |
Why?
|
| Tachycardia | 1 | 2003 | 29 | 0.060 |
Why?
|
| Pyridines | 1 | 2003 | 130 | 0.050 |
Why?
|
| Cocaine | 1 | 2003 | 170 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2006 | 382 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 2 | 1999 | 75 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2021 | 1259 | 0.050 |
Why?
|
| Vertebral Artery | 1 | 2000 | 11 | 0.050 |
Why?
|
| Analgesics, Opioid | 2 | 2014 | 552 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 2000 | 39 | 0.040 |
Why?
|
| Liver | 1 | 2006 | 1115 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2000 | 77 | 0.040 |
Why?
|
| Mutation | 1 | 2005 | 1294 | 0.040 |
Why?
|
| Heparin | 1 | 2000 | 92 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 1999 | 35 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2000 | 306 | 0.040 |
Why?
|
| Flumazenil | 1 | 1997 | 4 | 0.040 |
Why?
|
| Animals | 3 | 2007 | 13187 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 1997 | 70 | 0.040 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 1996 | 34 | 0.030 |
Why?
|
| Pain | 2 | 1996 | 379 | 0.030 |
Why?
|
| Skin | 2 | 1996 | 409 | 0.030 |
Why?
|
| Stroke | 1 | 2000 | 492 | 0.030 |
Why?
|
| Dextromethorphan | 1 | 2014 | 17 | 0.030 |
Why?
|
| Clonidine | 1 | 2014 | 26 | 0.030 |
Why?
|
| Amphetamines | 1 | 2014 | 29 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2000 | 1159 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 2903 | 0.030 |
Why?
|
| Wounds, Penetrating | 1 | 1994 | 41 | 0.030 |
Why?
|
| Anxiety | 1 | 1994 | 274 | 0.030 |
Why?
|
| Risk Factors | 1 | 2000 | 3613 | 0.020 |
Why?
|
| Age Factors | 2 | 2005 | 1087 | 0.020 |
Why?
|
| Species Specificity | 1 | 2005 | 192 | 0.020 |
Why?
|
| Oxygen | 2 | 1999 | 326 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2005 | 354 | 0.010 |
Why?
|
| Sex Factors | 1 | 2005 | 691 | 0.010 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 1999 | 6 | 0.010 |
Why?
|
| Prospective Studies | 2 | 1996 | 2364 | 0.010 |
Why?
|
| Anesthetics, Intravenous | 1 | 1999 | 24 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1999 | 84 | 0.010 |
Why?
|
| Narcotics | 1 | 1999 | 111 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2005 | 2772 | 0.010 |
Why?
|
| Meperidine | 1 | 1996 | 5 | 0.010 |
Why?
|
| Chlorpromazine | 1 | 1996 | 15 | 0.010 |
Why?
|
| Promethazine | 1 | 1996 | 12 | 0.010 |
Why?
|
| Sleep Stages | 1 | 1996 | 45 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1996 | 116 | 0.010 |
Why?
|
| Pruritus | 1 | 1996 | 44 | 0.010 |
Why?
|
| Leg | 1 | 1996 | 122 | 0.010 |
Why?
|
| Vomiting | 1 | 1996 | 75 | 0.010 |
Why?
|
| Motor Activity | 1 | 1996 | 229 | 0.010 |
Why?
|